The Key LARGO study: Building an international resource for glioblastoma epidemiology

Clicks: 1
ID: 315315
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #24 of 41 articles by views in Neuro-Oncology Practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Despite decades of epidemiological research, no glioblastoma risk factors have been identified that explain substantial risk. Prior studies often rely on single- or multi-center recruitment, which is costly and limits generalizability. To address this and increase the diversity of glioblastoma patients in epidemiological research, we have launched the Key LARGO study (NCT06625684, Key Longitudinal Associations with Risk and Glioblastoma Outcomes), an ongoing observational study of glioblastoma patients and their caregivers. Methods Key LARGO uses web-based enrollment and at-home biospecimen collection via mailed Tasso+ kits for self-collection of blood and serum. Participants complete a detailed, online survey (available in English or Spanish) on life history and health-related quality of life. Primary caregivers are enrolled to help report patient outcomes, including vital status. Results Recruitment began on December 10, 2024. As of February 28, 2026, 114 patients and 52 caregivers have consented. Of these, 96 consented to blood collection, 73 received kits, and 52 have returned samples. Eighty-two participants have completed the full study survey. Participants were 53% male, with a median age of 54 years (range 24-69) at time of diagnosis. Diagnoses occurred between 2007 and 2025. Most (96%) identified as White. Seven percent identified as Hispanic or Latino. Blood collection kits have been returned from the United States, Canada, Croatia, Italy, Indonesia, and the United Kingdom. Conclusions Key LARGO supports the feasibility of web-based recruitment and remote biospecimen collection in glioblastoma research. The current cohort is best suited for descriptive and hypothesis-generating analyses pending clinical/molecular validation and targeted recruitment.
Reference Key
openalex_W7162764646 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Courtney E. Wimberly, Michael C. Brown, Kyle M. Walsh, Quinn T Ostrom
Journal Neuro-Oncology Practice
Year 2026
DOI
10.1093/nop/npag052
URL
https://doi.org/10.1093/nop/npag052
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.